SYR127063

CAS No. 871026-18-5

SYR127063( BDBM92454 )

Catalog No. M24884 CAS No. 871026-18-5

SYR127063 (BDBM92454) is a potent and selective HER2 inhibitor, binds to HER2 in a reactive conformation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 272 In Stock
10MG 408 In Stock
25MG 672 In Stock
50MG 945 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SYR127063
  • Note
    Research use only, not for human use.
  • Brief Description
    SYR127063 (BDBM92454) is a potent and selective HER2 inhibitor, binds to HER2 in a reactive conformation.
  • Description
    SYR127063 (BDBM92454) is a potent and selective HER2 inhibitor, binds to HER2 in a reactive conformation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BDBM92454
  • Pathway
    Angiogenesis
  • Target
    HER/HSP
  • Recptor
    HER2/HER4/EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    871026-18-5
  • Formula Weight
    492.88
  • Molecular Formula
    C23H20ClF3N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:Soluble; Water: Insoluble
  • SMILES
    OCCOCCn(cc1)c2c1ncnc2Nc(cc1)cc(Cl)c1Oc1cc(C(F)(F)F)ccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Aertgeerts K, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem. 2011 May 27;286(21):18756-65.
molnova catalog
related products
  • TAS0728

    TAS0728 is a HER2 inhibitor with antitumor activity.

  • BMS 599626 2HCl

    BMS-599626 (AC480) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM) ~8-fold less potent to HER4 >100-fold to Lck VEGFR2 c-Kit MET etc.

  • EGFR-IN-99

    EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor with antiproliferative activity for the study of non-small cell lung cancer (NSCLC).